Robbins Arroyo LLP: Enzymotec Ltd. (ENZY) Stock Falls Nearly 40% After Violations of Federal Law are Revealed, According to Class Action


SAN DIEGO and MIGDAL HAEMEK, Israel, Sept. 10, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Enzymotec Ltd. (Nasdaq:ENZY) has filed a federal securities class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Act of 1933 and the Securities Exchange Act of 1934 in connection with the company's initial public offering on September 27, 2013. Enzymotec develops, manufactures, and markets innovative bio-active lipid ingredients used in various nutritional products.

View this information on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/enzymotec-ltd

Enzymotec is Accused of Failing to Disclose Compliance Issues Within the Chinese Market

According to the complaint, shares of Enzymotec first dropped 32% to close at $13.75 on May 14, 2014, after the company disclosed in a press release, along with its first quarter 2014 financial results, that new Chinese regulations will require infant formula manufacturers to make changes to their production line, resulting in lower than expected revenue. On August 5, 2014 shares of Enzymotec declined an additional 40% to close at $9.11 after the company announced that second quarter 2014 financial results were impacted in all aspects by the new Chinese regulations.

The complaint further alleges that Enzymotec made false and/or misleading statements and/or failed to disclose that: (i) the Chinese market was subject to material and readily identifiable compliance regulations from the Chinese government; (ii) the company's Chinese baby formula business was in jeopardy and subject to decreased revenue; (iii) the company breached its joint venture agreement with AarhusKarlshamn AB, therefore reducing its presence in China; and (iv) as a result, Enzymotec's positive statements about the company's business operations and prospects were unfounded.

Enzymotec Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.  



            

Contact Data